# Filing Detail

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-24-000024
Filing Date
2024-04-12
Accepted
2024-04-12 11:03:38
Documents
8
Period of Report
2024-04-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 6-K | a2024informationcircularfo.htm | 6-K | 20137
2 | EX-99.1 | onc-2024circularxfinal.htm | EX-99.1 | 543890
3 | EX-99.2 | oncolytics-proxy2024fina.htm | EX-99.2 | 9807
4 |  | image_3.jpg | GRAPHIC | 74787
5 |  | image_5.jpg | GRAPHIC | 305260
6 |  | image_7.jpg | GRAPHIC | 91994
7 |  | oncolytics-proxy2024fina001.jpg | GRAPHIC | 153883
8 |  | oncolytics-proxy2024fina002.jpg | GRAPHIC | 207511
| Complete submission text file | 0001129928-24-000024.txt |  | 1722744

Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 24840407
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)